Articles related to PSYCHOPHARMACOLOGY

The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.

A single-day inhaled mebufotenin regimen produced rapid, sustained symptom reductions through day 8 in 10 patients with postpartum depression, but the uncontrolled trial provides an early clinical signal rather than comparative efficacy evidence.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.

A post hoc analysis of five brexpiprazole trials found improved functioning in adults with schizophrenia, including those with baseline hostility or agitation. The exploratory findings require interpretation alongside trial-design limitations and lack of multiplicity adjustment.